Evidence map›Paper›PMID 31291885›Full record

ArticleBMC plant biology2019

Metabolic and transcriptional analyses in response to potent inhibitors establish MEP pathway as major route for camptothecin biosynthesis in Nothapodytes nimmoniana (Graham) Mabb.

Gulzar A Rather, Arti Sharma, Syed Mudassir Jeelani, Prashant Misra, Veenu Kaul, Surrinder K Lattoo

Open access · goldAbstract read
In one paragraph

Article in BMC plant biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gulzar A RatherPlant Biotechnology Division, CSIR- Indian Institute of Integrative Medicine, Canal Road, Jammu Tawi, 180001, India.
Arti SharmaPlant Biotechnology Division, CSIR- Indian Institute of Integrative Medicine, Canal Road, Jammu Tawi, 180001, India.
Syed Mudassir JeelaniPlant Biotechnology Division, CSIR- Indian Institute of Integrative Medicine, Canal Road, Jammu Tawi, 180001, India.
Prashant MisraPlant Biotechnology Division, CSIR- Indian Institute of Integrative Medicine, Canal Road, Jammu Tawi, 180001, India.
Veenu KaulDepartment of Botany, University of Jammu, Jammu Tawi, 180006, India.
Surrinder K LattooPlant Biotechnology Division, CSIR- Indian Institute of Integrative Medicine, Canal Road, Jammu Tawi, 180001, India. sklattoo@iiim.ac.in.
Indian Institute of Integrative Medicine · INUniversity of Jammu · IN

Funding

CSIR-IIIM, Jammu MLP3012 (WP 7)
6 · The paper itself

Abstract

backgroundNothapodytes nimmoniana, a plant of pivotal medicinal significance is a source of potent anticancer monoterpene indole alkaloid (MIA) camptothecin (CPT). This compound owes its potency due to topoisomerase-I inhibitory activity. However, biosynthetic and regulatory aspects of CPT biosynthesis so far remain elusive. Production of CPT is also constrained due to unavailability of suitable in vitro experimental system. Contextually, there are two routes for the biosynthesis of MIAs: the mevalonate (MVA) pathway operating in cytosol and the methylerythritol phosphate (MEP) pathway in the plastids. Determination of relative precursor flux through either of these pathways may provide a new vista for manipulating the enhanced CPT production.

resultsIn present study, specific enzyme inhibitors of MVA (lovastatin) and MEP pathways (fosmidomycin) were used to perturb the metabolic flux in N. nimmoniana. Interaction of both these pathways was investigated at transcriptional level by using qRT-PCR and at metabolite level by evaluating secologanin, tryptamine and CPT contents. In fosmidomycin treated plants, highly significant reduction was observed in both secologanin and CPT accumulation in the range 40-57% and 64-71.5% respectively, while 4.61-7.69% increase was observed in tryptamine content as compared to control. Lovastatin treatment showed reduction in CPT (7-11%) and secologanin (7.5%) accumulation while tryptamine registered slight increase (3.84%) in comparison to control. These inhibitor mediated changes were reflected at transcriptional level via altering expression levels of deoxy-xylulose-5-phosphate reductoisomerase (DXR) and hydroxymethylglutaryl-CoA reductase (HMG). Further, mRNA expression of four more genes downstream to DXR and HMG of MEP and MVA pathways respectively were also investigated. Expression analysis also included secologanin synthase (SLS) and strictosidine synthase (STR) of seco-iridoid pathway. Present investigation also entailed development of an efficient in vitro multiplication system as a precursor to pathway flux studies. Further, a robust Agrobacterium-mediated transformed hairy root protocol was also developed for its amenability for up-scaling as a future prospect.

conclusionsMetabolic and transcriptional changes reveal differential efficacy of cytosolic and plastidial inhibitors in context to pathway flux perturbations on seco-iridoid end-product camptothecin. MEP pathway plausibly is the major precursor contributor towards CPT production. These empirical findings allude towards developing suitable biotechnological interventions for enhanced CPT production.

Indexed as

Antineoplastic Agents, PhytogenicBiosynthetic PathwaysCamptothecinGene Expression Regulation, PlantMagnoliopsidaPlants, MedicinalAntineoplastic Agents, PhytogenicCamptothecinCamptothecinFosmidomycinLovastatinMEP and MVA pathwayNothapodytes nimmonianaShoot cultureTransformed hairy roots

Identifiers

PMID31291885
PMCPMC6617690
OpenAlexW2960092888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.